The sodium/glucose cotransporter 2 (SGLT2) inhibitors, canagliflozin and dapagliflozin, offer a therapeutic alternative in T2DM management through the utilization of a unique mechanism of action to provide intensified glycemic control. This article will evaluate the safety and efficacy of dapagliflozin in...
Aims:Sodium-glucose co-transporter inhibitors (SGLT2i) are emerging as a new treatment for heart failure (HF) after demonstrating favorable clinical outcomes in several randomized controlled trials (RCTs). In this meta-analysis, we assessed the safety of SGLT2i in the trials that prespecified ...
Abbreviations: MoA, mechanisms of action; RAAS, renin angiotensin aldosterone system; SNS, sympathetic nervous system. Figure 2. SGLT2is and renal protection: from biological mechanisms to clinical benefits. Renal protection by SGLT2 inhibitors is likely multifactorial. In the short term, SGLT2is ...